NASDAQ:TTNP

Titan Pharmaceuticals (TTNP) Stock Forecast, Price & News

$0.78

+0.01 (+1.31%)

(As of 06/1/2023 ET)

Compare

Today's Range: $0.75
▼
$0.78
50-Day Range: $0.73
▼
$0.83
52-Week Range: $0.39
▼
$1.59

Volume: 11,138 shs
Average Volume: 21,068 shs
Market Capitalization: $11.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Titan Pharmaceuticals (NASDAQ:TTNP) Stock

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Stock News Headlines

June 1, 2023 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

May 26, 2023 | finance.yahoo.com

TTNP - Titan Pharmaceuticals, Inc.

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

May 25, 2023 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

May 23, 2023 | sports.yahoo.com

Watch: Prowling tiger bows to ‘titan herd’ of elephants

May 17, 2023 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

May 1, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

April 30, 2023 | americanbankingnews.com

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Large Increase in Short Interest

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

April 22, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

March 22, 2023 | seekingalpha.com

TTNP Titan Pharmaceuticals, Inc.

March 21, 2023 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com

December 15, 2022 | finance.yahoo.com

Titan Pharmaceuticals Provides Shareholder Update

December 12, 2022 | nz.finance.yahoo.com

Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

November 21, 2022 | bizjournals.com

Chapel Hill surgical tech company shapes plan to keep Nasdaq listing

November 17, 2022 | finance.yahoo.com

Titan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)

November 4, 2022 | msn.com

Titan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results Today

August 17, 2022 | benzinga.com

Titan Pharmaceuticals Announces Board Expansion...

August 16, 2022 | finance.yahoo.com

Titan Pharmaceuticals Announces Board Expansion and Management Changes

July 11, 2022 | insidermonkey.com

Hedge Fund and Insider Trading News: George Soros, Jim Simons, Three Arrows Capital, Rocket Companies Inc (RKT), Titan Pharmaceuticals, Inc. (TTNP), and More

July 11, 2022 | finance.yahoo.com

Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders

July 9, 2022 | finance.yahoo.com

Here's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn Situation

July 6, 2022 | benzinga.com

Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study

July 5, 2022 | nasdaq.com

Titan Pharma Says FDA Clears IND Application For Nalmefene Implant

July 5, 2022 | finance.yahoo.com

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

June 10, 2022 | finance.yahoo.com

Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.

April 25, 2022 | apnews.com

Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.

See More Headlines

TTNP Price History

30 days | 90 days | 365 days | Advanced Chart

TTNP Company Calendar

Last Earnings: 3/30/2021
Today: 6/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TTNP
CUSIP: N/A
CIK: 910267
Web: www.titanpharm.com
Phone: (650) 244-4990
Fax: 650-244-4956
Employees: 11
Year Founded: 1992

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,210,000.00
Net Margins: -2,017.49%
Pretax Margin: -2,017.49%
Return on Equity: -363.89%
Return on Assets: -179.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.73
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $560,000.00
Price / Sales: 20.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: -38.10

Miscellaneous

Outstanding Shares: 15,020,000
Free Float: 10,827,000
Market Cap: $11.45 million
Optionable: Optionable
Beta: 1.10

Social Links

Key Executives

David Elliot Lazar
Chairman, Chief Executive & Financial Officer

Katherine L. Beebe-DeVarney
President, Chief Operating Officer & Director

Brian E. Crowley
Vice President-Finance

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

TTNP Stock - Frequently Asked Questions

How have TTNP shares performed in 2023?: Titan Pharmaceuticals' stock was trading at $0.7831 on January 1st, 2023. Since then, TTNP stock has decreased by 2.7% and is now trading at $0.7620.
View the best growth stocks for 2023 here.
Are investors shorting Titan Pharmaceuticals?: Titan Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 46,200 shares, a decline of 26.1% from the April 30th total of 62,500 shares. Based on an average daily trading volume, of 15,000 shares, the days-to-cover ratio is presently 3.1 days.
View Titan Pharmaceuticals' Short Interest.
How were Titan Pharmaceuticals' earnings last quarter?: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings data on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative trailing twelve-month return on equity of 363.89% and a negative net margin of 2,017.49%.
When did Titan Pharmaceuticals' stock split?: Shares of Titan Pharmaceuticals reverse split on the morning of Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).
What is Titan Pharmaceuticals' stock symbol?: Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."
How do I buy shares of Titan Pharmaceuticals?: Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Titan Pharmaceuticals' stock price today?: One share of TTNP stock can currently be purchased for approximately $0.76.
How much money does Titan Pharmaceuticals make?: Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $11.45 million and generates $560,000.00 in revenue each year.
How can I contact Titan Pharmaceuticals?: Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.

This page (NASDAQ:TTNP) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial